

31 May - 6 June 2010

COMPANY SPOTLIGHT

- **Array BioPharma Inc.** (Boulder) announced the presentation of positive Phase 1 clinical data for its novel kinesin spindle protein (KSP) inhibitor, ARRY-520. The data, which were presented at the American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago, Illinois, indicate that ARRY-520 was well tolerated and has shown encouraging preliminary results in the treatment of multiple myeloma. ARRY-520 is a novel, first-in-class, highly potent, selective KSP inhibitor currently advancing into a single-agent Phase 2 clinical trial and combination trials in patients with multiple myeloma. The poster is available as a PDF on Array's website.
- **Allos Therapeutics, Inc.** (Westminster) reported new analyses of data from the Company's pivotal PROPEL trial of FOLOTYN® (pralatrexate injection) in patients with relapsed or refractory peripheral T-cell lymphoma (PTCL). These analyses demonstrated that patients who responded to FOLOTYN had up to a 44% reduction in risk of death based on independent central review of response ($P=.07$), and up to a 56% reduction in risk of death based on investigator review of response ($P<.01$), when compared with patients whose disease did not respond to FOLOTYN. These analyses also demonstrated that patients with stable disease who received FOLOTYN had a reduction in the risk of death when compared to patients with progressive disease.
- **Spectranetics Corporation** (Colorado Springs), Array BioPharma Inc. (Boulder), and Allos Therapeutics, Inc. (Westminster) all announced they will present at the Jefferies Global Life Sciences Conference being held June 8-11, 2010 at the Grand Hyatt Hotel in New York City. Allos also announced it will present at three other conferences in June: the BofA Merrill Lynch 2010 SMid Cap Conference (Boston), the 9th Annual Needham Healthcare Conference (New York City), and ThinkEquity's Mid Year Check-Up on Healthcare Conference (New York).

SQUARE PEGS

- **The Colorado Office of Economic Development and International Trade** has awarded 2009-2010 grants totaling \$352,000 to seven Colorado State University bioscience professors. The Colorado Legislature created the Bioscience Discovery Evaluation Grant Program in 2006 to increase the research and development of new bioscience technology in Colorado research institutions. The grants are intended to accelerate commercialization of new discoveries and support new business development. The program has since been amended to also expedite the research and production of biofuels.
- **C2D2**, a program of CSU Ventures, Inc. (CSUV) funded by a grant from the State of Colorado Office of Economic Development and International Trade, invites researchers to submit drug discovery-related proposals to be funded through C2D2 sponsored grants. The grants (up to \$50K/project) incentivize collaborative partnerships and are intended for short term (e.g. 3-9 month) projects. See the attached RFP for more information.

- On Friday, May 21, the IRS released guidance on the Therapeutic Discovery Tax Credit, describing the process by which firms can apply to have their research projects certified as eligible for the credit. Companies may submit applications for certification beginning June 21, 2010, and applications must be postmarked no later than July 21, 2010. As part of the review process for research projects, the Department of Health and Human Services (HHS) will evaluate each project for its potential to produce new therapies or reduce health care costs. Only projects that show a reasonable potential to meet these goals will be certified as eligible for the credit. The IRS will issue certifications by the end of October based on the determinations made by HHS. Please see the attached document provided by BIO for more information, or contact Jamison Meredith, Senior Manager, Business Tax Services at Ernst & Young for specific questions, or assistance with filing at jamison.meredith@ey.com.
- **The Medical Career Collaborative (MC2)** program at **The Children's Hospital** provides high school students from disadvantaged socio-economic backgrounds an opportunity to gain experience and exposure in the fields of health, medicine and bioscience. This two year program includes a paid internship at Children's and help with college preparation. Over the last ten years, 200 students have enrolled in MC2 and all have graduated from high school. The program is currently seeking cosponsors from the bioscience community. Please see the attached document for more information.

UPCOMING EVENTS

- **CBSA's** Bioscience Bogey Tournament, presented by Accera Pharma, will take place on June 14 at the Fox Hollow Golf Course. Several sponsorship opportunities are still available. Visit <http://www.cobiosciencebogey.com> for more information or to register.
- **Polsinelli Shughart** will hold a webinar on June 9 during which top health care public policy attorneys will discuss health care reform as it relates to the medical device community. Click [here](#) to register.
- **FreeMind Group** will hold a webinar on June 9 at 10:30-11:30AM MST to present the clinical funding trends in the NIH. This webinar will discuss shifting dynamics of clinical funding, new opportunities, challenges, and the difference between a standard grant application and a clinical one. This webinar is designed for companies and researchers from the Academia at, or entering, the stage of clinical development, who wish to increase their success rates and the total amount of funding awarded. The webinar is free of charge. To register, please contact Hannah Rosencweig at (617) 648-0340, ext. 221, or at Hannah@freemindconsultants.com.
- **Fitzsimons Redevelopment Authority, Fitzsimons BioBusiness Partners, Colorado BioScience Association & University of Colorado** will be holding a Core Labs Show to showcasing the valuable resources available in the Core Labs at University of Colorado and National Jewish Health. The event will take place on June 15 from 9:30-12:30pm at the Bioscience Park Center in Aurora. Please see the attached PDF for more info.
- **BioMARC**, the regional training center for product translation at Colorado State University, will be holding a lunch-and-learn short course sponsored by GE Healthcare on

Tuesday, June 29, on "Applying Filtration, WAVE Reactor, and Chromatography Single-Use Technologies to BioProcessing". [Click here for more info or to register.](#)

- **Denver Public Schools** announced that it will be hosting a citywide career fair for its eighth graders. The event will be held on Wednesday, October 20, 2010 at the National Western Complex off of I-70 and Brighton Blvd. The primary objective of the event is to expose the students to the vast scope of careers available to them and to help them plan for their future. The school system is seeking companies to exhibit - Please see the attached documents for more information or to register your company to take part.

SAVE THE DATE: Please join us for the **Roche Colorado Corporation** Peptide Symposium (RCCPS) on September 14 – 16, 2010 at the St. Julian Hotel and Spa in Boulder, CO. The program highlights include; Peptides in the Clinic; Peptide Drug Delivery; Emerging Technologies; Advances in Peptide Chemistry; and, Quality by Design in Peptides. The following link www.rccps.org, and attachments will provide additional information on the conference and sponsorship opportunities. We look forward to showcasing Colorado as a leader in Peptides at this conference and hope you will be able to join us! Please see attached flyer for information on sponsorship opportunities.